Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$359.50M+3476.05%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alan S. Bash
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,300
- Beta
- 0.40
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.05
Financials
Revenue
$359.50M+3476.0%Net Income
$51.70MEBITDA
$64.30MFree Cash Flow
$-41.50MEPS (diluted)
$0.26Shares Outstanding (diluted)
193.80M+93.4%Operating Expenses
$165.10MCash & Debt
$852.50MRevenue by Segment (annual)
$4.91MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.03B | $-296.80M | $-1.60 |
| 2024 | $627.24M | $-177.03M | $-0.97 |
| 2023 | $285.14M | $-518.25M | $-2.94 |
| 2022 | $117.00M | $-446.35M | $-2.81 |
| 2021 | $68.83M | $-403.58M | $-2.74 |
| 2020 | $75.00M | $-266.37M | $-2.57 |
| 2019 | $61.80M | $-101.59M | $-1.01 |
| 2018 | $49.13M | $-2.78M | $-0.03 |
| 2017 | $23.59M | $9.37M | $0.07 |
Valuation
LEGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
46-23.81%Social Signal Score
Mentions (15)
- Newsseekingalpha.com·5d ago·Neutral
Legend Biotech: The Market Is Missing The Bigger Picture Legend Biotech Corporation shares have plunged 34.5% after briefly rallying to $24.3 on November 9, partly amid the broader selloff in AI-related stocks. I continue to take advantage of market pessimism by steadily accumulating LEGN. Sales of LEGN's blockbuster, Carvykti, developed jointly with J&J, increased 8.1% quarter-on-quarter to $710 million.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Positive
What Legend Biotech (LEGN) Said on Its Q3 Earnings Call Legend Biotech NASDAQ: LEGN reported 36% growth in third-quarter global net trade sales of its multiple myeloma treatment CARVYKTI, while executives said slower-than-anticipated gains in earlier-line U.S. patients and international launch delays could temper sales expectations.
View source ↗ - 4chan /biz/biz·13d ago·Neutral
>>62877407 Legend
View source ↗ - News (RSS)nyt·15d ago·Neutral
A ‘Legend of Zelda’ Game Is Reborn and ’90s Nostalgia Fans Are All In Nintendo’s “Legend of Zelda: Ocarina of Time” was released in 1998. Now, its remake has some fans giddily reliving their childhoods.
View source ↗ - News (RSS)bbc·17d ago·Positive
India's costliest film retells a beloved Hindu epic - but divides critics Easily the most anticipated Bollywood film of the year, Ramayana: Rise of a Legend is the first of two parts.
View source ↗ - Newszacks.com·24d ago·Positive
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average From a technical perspective, Legend Biotech Corporation Sponsored ADR (LEGN) is looking like an interesting pick, as it just reached a key level of support. LEGN recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
View source ↗ - Newszacks.com·26d ago·Neutral
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors After reaching an important support level, Legend Biotech Corporation Sponsored ADR (LEGN) could be a good stock pick from a technical perspective. LEGN surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m.
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive CARVYKTI's quarterly sales reached $710 million, but Legend's high expenses have kept recurring profitability low. Q2 results show improving operating leverage, with collaboration revenue growing faster than associated costs. I rate LEGN a cautious buy, given the commercial growth opportunity but limited margin of safety.
View source ↗ - Newsglobenewswire.com·58d ago·Positive
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
View source ↗ - Newsglobenewswire.com·73d ago·Positive
…vidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
View source ↗ - News247wallst.com·103d ago·Positive
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history.
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
Legend Biotech Q2 Earnings Call Highlights Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call.
View source ↗
Earnings
Tue, Mar 9(in 4 months)
Consensus estimate $0.06 per share
Typical surprise +15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$0.14 vs $0.01beat
- Tue, Aug 11$0.09 vs $0.12miss
- Tue, May 12$-0.15 vs $-0.02miss
- Tue, Mar 10$-0.08 vs $-0.17beat
- Wed, Nov 12$-0.11 vs $-0.13beat
- Mon, Aug 11$-0.34 vs $-0.11miss
Estimates and results for LEGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LEGN officers and directors.
- Bought
- $346k
- Sold
- $567k
3 trades
5 trades
- Zhang Ingridbought
- Salovey Peterbought
- Salovey Peterbought
- Sanders Corazon (corsee) D.sold
- Santos Carlos Esold
- Casey Patrick Johnsold
- Huang Yingsold
- Huang Yingsold
37 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LEGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
